Pertuzumab is a HER2 dimerization inhibitor that binds to a different epitope on HER2 than Herceptin. The drug inhibits HER2 dimer formation with other HER family members, such as HER3 and HER1.

Enliven Therapeutics (ELVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam ...

Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment ...

in a first for both HER2 inhibitors and ADCs. Enhertu (trastuzumab deruxtecan) can be used to treat adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have ...

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical ...

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...

These are targeted drugs that can be used for women with a common type of breast cancer: hormone receptor-positive and HER2-negative. Currently, there are three CDK4/6 inhibitors approved to treat ...